We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Reforms to ensure that medical device regulation is fit for purpose for software products, including artificial intelligence (AI).
This guidance clarifies the expectations on the application of the further pharmacovigilance provisions set out within the updated CIR 520/2012 for UK authorised products.
Outlining the principles for the management and oversight of the import of investigational medicinal products (IMPs) to Great Britain from listed countries.
Points to consider when using real-world data in clinical studies
Information on practical arrangements for notification, what should and should not be classified as a “serious breach” and what must be reported.
Guidance on how to license electronic cigarettes and other inhaled nicotine-containing products (NCPs) as medicines in the UK.
The stepwise implementation programme aims to deliver the first wave 1 regulatory assessment in 14 calendar days for qualifying applications by the end of 2026.
This publication clarifies which regulatory guidelines should be followed, and which apply, in the development of phage therapeutic products.
Which professions can act as an investigator, training and experience expectations, provision of medical support and delegation of activities.
Approved countries for batch testing and importation of medicines
A list of herbal ingredients that are banned or restricted for unlicensed medicines.
10 guiding principles that can inform the development of good machine learning practice (GMLP).
How manufacturers in Northern Ireland should undertake a clinical investigation for medical devices to ensure they comply with EU medical device regulations.
A proposed format to help prepare responses to good distribution practice (GDP)/good manufacturing practice (GMP) post inspection letters.
Information on the implementation of changes to pharmacovigilance for medicines authorised in the UK following the agreement of the Windsor Framework.
Information and recommendations for manufacturers on the preparation and presentation of a periodic safety update report (PSUR).
Sets out medicines that can be moved to Northern Ireland to meet patient need.
A practical guide to using medical devices in a range of healthcare settings.
A 5-year deal setting out how community pharmacy will support delivery of the NHS Long Term Plan.
The approach the MHRA intends to take for products approved or pending in decentralised procedure (DCP) or mutual recognition procedures (MRP).
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).